iBio Inc (IBIO) Quote

Why is IBIO stock going down?

ChatGPT said:
iBio Inc. (IBIO) has experienced a decline in its stock price due to several factors:?

Public Offering at a Discounted Price: In December 2023, iBio announced a public offering of 2.25 million shares at $2 each, significantly below the prior closing price of $2.70. This offering raised concerns about shareholder dilution, contributing to a 41% drop in stock price at that time.
INVESTORPLACE
?
Reverse Stock Split: In November 2023, the company executed a 20-to-1 reverse stock split, reducing the number of outstanding shares from approximately 28.1 million to 1.4 million. While reverse splits can increase share prices temporarily, they often signal financial distress and can lead to decreased investor confidence. ?

Financial Performance and Cash Flow Concerns: For the fiscal year ending June 30, 2024, iBio reported a net loss of $24.9 million, an improvement from the previous year's loss but still indicative of ongoing financial challenges. The company also faced negative cash flows, raising concerns about its ability to fund operations and growth initiatives. ?

Insider Selling and Dilution Risks: There have been instances of insider stock sales, which can be perceived negatively by investors. Additionally, previous agreements, such as those with Aspire Capital Fund and Lincoln Park Capital Fund, involve the issuance of substantial shares, potentially diluting existing shareholders and impacting stock value. ?

These factors collectively have contributed to the downward pressure on iBio's stock price.

On February 10, 2025 PR they said revenue of $0.2 million was reported for services provided to a collaborative partner during the quarter ended Dec. 31, 2024.

R&D and G&A expenses for the second quarter of fiscal 2025 totaled approximately $4.6 million

Cash, cash equivalents and restricted cash as of Dec. 31, 2024, was approximately $7.2 million, inclusive of $0.2 million of restricted cash.

Lets be generous and add the $650,000 by the members of its Board of Directors and Officers

Why only $650K though for this "Gold Mine".

Was it to give the illusion to save their RSUs and Options?

Using 'simple math' the company had $7.2M in cash in December. Add the $650K

They are currently throwing over $1.5M out the window per month.

That gives the company approximately cash for FIVE months

Jan., Feb. Mar, Apr, May

Who is going to pony up $10M more to keep the boat afloat this year?

Why is iHub still showing AMEX?

Probably because the $6.33 price for the last trade on AMEX is a hell of a lot better than the current $4.50 price on NASDAQ, and IHUB wants to keep IBIO investors from sinking into depression. IBIO share price has been on a steady decline since the move to the new exchange.



Some have posted the move to the NASDAQ exchange would be "revealing", while the company CEO tried to spin it as a positive move for investors. So far it's very revealing.

Perhaps someone is investing another six figures here, loading up on cheaper shares as the price continues lower, assuming they have that much remaining after previous catastrophic investments... clicking the BUY button with one hand while eating a slice of delicious Domino's pizza with the other hand.

Notice the sour look on the investor's face. Even a slice of delicious Domino's pizza can't change the fact they've picked another loser investment, and trying to save face by averaging down as the share price continues to tank. No zip code change in this guy's future.

Another great week of IBIO being "revealed". Here's some encouragement and support for the IBIO investor.

What?

Great to hear from you.

"Your bs is done with IBIO Sir!!!"

I 'do' get why you are responding on Monday, January 20, 2025 12:32:13 AM

to a post I made SIX MONTHS EARLIER on Friday, July 26, 2024 7:57:30 AM LOL

Seems to be a 6 month reaction in hindsight, but I welcome and will return the favor in spaces

where I said...

Toast...

"We are filing this registration statement with the Securities and Exchange Commission (the “SEC”) using a “shelf” registration process. Under this registered “shelf,” in the future, we may, from time to time, sell any combination of the securities described herein, in one or more offerings, up to a maximum aggregate offering price of $150,000,000. This prospectus provides you with a general description of the securities."

Hope spring internal.

Some have invested their kids tuition into IBIO only to send them to maid school.

Risk / Reward

Hey...

Why is iHub still showing AMEX?

iBIO got kicked off AMEX

Booted to the CURB

Surprised the 'stock analyst' that has been promoting this stock since $2000 plus is still trying to still sucker noobs.

I missed all the fun.

Did iBIO get booted off AMEX?

Who didn't see that coming?

What tale is iBIO spinning now?

Love the top spin on how that is a positive.

Only ones going 'all in' are flipping gambler's

For my On Topic post of the day I would suggest iBIO would probably make more money in some kind of Molly Maids gig.
Molly Maid Franchise: Average Sales ($855K) vs. Cost ($133K-$191K)

Maybe iBIO could buy Molly Maids with all the cash on hand they have.

Oh wait...

How much do they have left before they dilute again and do another RS?

Very revealing on Nasdaq, yessiree!! I wonder what next week on Nasdaq will reveal.

Yep! Very revealing. Great launch on the new exchange.

tomorrows 3/4/25 NAS uplisting should be revealing

$iBio

That's great, but your chart is the 6-month chart, not the 52-week chart.

Here's the 52 week IBIO chart, showing the new high isn't that much above the high at the start of the period.




Here's the 2-year IBIO chart.



The 3-year IBIO charts looks even worse.



I hope IBIO can find success this time. There are some posting here who were BUY! BUY! BUYING! shares of IBIO at prices at the much higher prices on these longer-term charts, and will have a long way to go before even remotely breaking even. And the multiple reverse splits haven't helped matters for shareholders.

IBIO, new 52 week high

To be fair, I made the following request to the ChatGPT AI model:

Compare the listing requirements for NYSE American and NASDAQ Capital Markets, including requirements for a company on either exchange to remain listed.

———————————————————————————————
A transfer from NYSE American to NASDAQ Capital Market can be viewed from multiple perspectives, depending on the company's financial situation, growth strategy, and investor perception.

Is It Easier to Meet NASDAQ Capital Market Requirements?

In general, NASDAQ Capital Market has slightly higher requirements than NYSE American in some aspects, such as:

• Stock Price: NASDAQ requires a minimum of $4/share for initial listing, while NYSE American allows as low as $2/share under some standards.

• Stockholders' Equity: NASDAQ requires at least $5 million for initial listing (under the Equity Standard), while NYSE American requires $4–$6 million depending on the listing path.

• Market Capitalization: NYSE American has an initial market cap requirement of $50 million (or lower in alternative standards), while NASDAQ Capital Market has a lower continued listing requirement at $35 million.

If a company is struggling to meet NYSE American's continued listing requirements but still qualifies for NASDAQ Capital Market, the move can help avoid delisting and provide a fresh start on a well-recognized exchange.

How is the Move Perceived?

• Neutral or Positive: If the transfer is due to a strategic decision (e.g., better alignment with NASDAQ’s technology-focused investor base), it may be seen as a neutral or positive move.

• Negative: If the move happens because the company fails to meet NYSE American’s requirements, investors might see it as a downgrade or a sign of financial trouble.

Other Considerations

• NASDAQ has a more tech-friendly reputation: If the company operates in tech, biotech, or growth industries, moving to NASDAQ might attract more institutional and retail investors.

• Market Perception Matters: Investors may view a transfer as an attempt to avoid delisting if the company struggles to meet NYSE American’s standards.

• NASDAQ offers lower listing fees: Annual fees on NASDAQ Capital Market tend to be lower than on NYSE American.

Final Verdict

• If the company voluntarily moves for strategic reasons, it’s a neutral or positive shift.

• If the move is forced due to non-compliance, it may be seen as a negative signal by investors.

• While the requirements aren’t significantly easier, NASDAQ Capital Market does offer a lower continued market cap threshold, which might help struggling companies stay listed.

This is a transfer from NYSE to NASDAQ. Not the same thing as uplisting. NASDAQ's Capital Market requirements are less stringent than NYSE American and easier for IBIO to remain listed on a national exchange. In that regard it could be viewed as a necessary move for the company. The last paragraph below spins it as a positive move, but that's what companies do. Maybe it will be. But no one should be fooled into believing this is an uplisting that occurs when a company is moving to the next higher tier of corporate and financial performance.
March 4th is iBio's Nasdaq uplisting
iBio to Begin Trading on the Nasdaq Stock Exchange

SAN DIEGO, Feb. 19, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO), an AI-driven innovator of precision antibody therapies, today announced that iBio’s common stock has been approved for listing on the Nasdaq Capital Market and iBio will transfer its stock exchange listing to Nasdaq Capital Market from the NYSE American. The Company expects to begin trading as a Nasdaq-listed company on Mar 4, 2025, and will continue to trade under the symbol “IBIO.” The Company’s common stock will continue to trade on the NYSE American until the market close on Mar 3, 2025.

Martin Brenner, Ph.D., DVM, iBio’s CEO and Chief Scientific Officer, commented, “We are pleased to announce our listing on the Nasdaq Capital Market and to join a community of leading biotech companies. We believe the move to Nasdaq will improve the visibility of our common stock, enhance trading liquidity in our shares, and provide us with greater exposure to institutional investors.”

https://ir.ibioinc.com/news-events/press-releases/detail/234/ibio-to-begin-trading-on-the-nasdaq-stock-exchange

Form 4's - simply stunning quantity of buys from insiders

https://ih.advfn.com/stock-market/AMEX/ibio-IBIO/news

March 4th is iBio's Nasdaq uplisting

thinking they have major news to announce - on top of the Nasdaq milestone uplisting

iBIO...!

IBIO $5.68 coming to the rescue so munch for Chinese take out.. Bird Flu in Cats New Jersey
Two domestic cats in New Jersey have tested positive for the highly pathogenic avian influenza (H5N1) in Hunterdon County. One feral cat developed severe disease, including neurologic signs, and was euthanized. Another indoor-outdoor cat also tested positive, and tests on other cats on the property are pending.Additional Details:Symptoms in Cats: Clinical signs of bird flu in cats can include respiratory signs (discharge from the eyes and mouth, sneezing, coughing, difficulty breathing) and neurologic signs.Transmission: Cats can contract the virus through exposure to infected birds or other animals, contaminated environments, or by consuming raw/undercooked meat or milk from infected sources.Prevention: Pet owners are advised to avoid feeding cats raw milk or meat, avoid contact with sick or dead birds and wildlife, and thoroughly wash hands and change clothes after handling sick animals.Human Risk: While the risk of H5N1 infection to the general population remains low, close contact with infected animals can pose a risk. No human cases have been reported in New Jersey.Reporting: New Jersey residents should contact their veterinarian if they have concerns about their pets. Suspect feline cases should be reported to the New Jersey Department of Health at 609-826-4872 or zoonoticrn@doh.nj.gov.

IBIO $5.60 to the moon ...lol New Jersey domestic cats caight the bird 🦅 flu...$TRAW $GOVX $IBIO
Eggs to the moon 🥚 

All in last couple months.... interesting 

Good luck with IBIO. I hope when it reaches $1,000/share you will have recovered all of your prior losses in this turd.

Insiders got lots of free shares and 13GS show some big owners invested ..
424B3 (Prospectus) 2025-02-11iBio, Inc. (IBIO) 8-K (Current report) 2025-02-102025-02-10iBio, Inc. (IBIO) EFFECT (SEC order) 2025-02-10iBio, Inc. (IBIO) 10-Q (Quarterly report) 2025-02-102024-12-31iBio, Inc. (IBIO) S-8 (Registration statement) 2025-01-31iBio, Inc. (IBIO) S-3 (Registration statement) 2025-01-31iBio, Inc. (IBIO) SCHEDULE 13G/A 2025-01-30iBio, Inc. (IBIO) 
Crutcher Patrick J SCHEDULE 13G 2025-01-29iBio, Inc. (IBIO) 
Crutcher Patrick J 4 (Insider trading report) 2025-01-132025-01-10Banjak Marc 
iBio, Inc. 8-K (Current report) 2025-01-132025-01-10iBio, Inc. (IBIO) 4 (Insider trading report) 2025-01-132025-01-10Duran Felipe 
iBio, Inc. 4 (Insider trading report) 2025-01-132025-01-10Parada Antonio Bernardino Guimaraes 
iBio, Inc. 4 (Insider trading report) 2025-01-132025-01-10Brenner Martin 
iBio, Inc. 4 (Insider trading report) 2025-01-132025-01-10Sender Gary 
iBio, Inc. 4 (Insider trading report) 2025-01-132025-01-10Arkowitz David 
iBio, Inc. 4 (Insider trading report) 2025-01-132025-01-10Clark William D 
iBio, Inc. 8-K (Current report) 2025-01-102025-01-10iBio, Inc. (IBIO) SCHEDULE 13G/A 2025-01-03iBio, Inc. (IBIO) 
SABBY MANAGEMENT, LLC 8-K (Current report) 2025-01-022024-12-31iBio, Inc. (IBIO) 4 (Insider trading report) 2024-12-092024-11-21Parada Antonio Bernardino Guimaraes 
iBio, Inc. 3 (Initial insider holdings report) 2024-12-092024-11-21Parada Antonio Bernardino Guimaraes 
iBio, Inc. 4 (Insider trading report) 2024-11-252024-11-21Sender Gary 
iBio, Inc. 8-K (Current report) 2024-11-252024-11-21iBio, Inc. (IBIO) 4 (Insider trading report) 2024-11-252024-11-21Schimmelpennink Evert B. 
iBio, Inc. 4 (Insider trading report) 2024-11-252024-11-21Kropotova Alexandra 
iBio, Inc. 4 (Insider trading report) 2024-11-252024-11-21Clark William D 
iBio, Inc. 4 (Insider trading report) 2024-11-252024-11-21Arkowitz David 
iBio, Inc. 3 (Initial insider holdings report) 2024-11-252024-11-21Arkowitz David 
iBio, Inc. SC 13G (Beneficial ownership report) 2024-11-14iBio, Inc. (IBIO) 
Ikarian Capital, LLC SC 13G/A (Beneficial ownership report) 2024-11-14iBio, Inc. (IBIO) 
ADAR1 Capital Management, LLC

8-K (Current report) 2025-02-192025-02-19iBio, Inc. (IBIO) SCHEDULE 13G/A 2025-02-14iBio, Inc. (IBIO) 
Opaleye Management Inc. SCHEDULE 13G/A 2025-02-14iBio, Inc. (IBIO) 
ADAR1 Capital Management, LLC

Filing entity/person4 (Insider trading report) 2025-02-242025-02-21Duran Felipe 
iBio, Inc. 4 (Insider trading report) 2025-02-242025-02-21Banjak Marc 
iBio, Inc. 4 (Insider trading report) 2025-02-242025-02-21Brenner Martin 
iBio, Inc.

right right right...!

sad to see you soooo puzzled - eh Joey...?

Do you think there's a buyout or partnership coming?  The 2 new members of the BoD seem to have strong experience in M&A in the Pharma industry.  

$4.92 Looking good will hold to $20s

deep pocket offshore interest

Anyone know what's driving price here?  Maybe some deal is about to be announced?  

only 9-Mil share float

noice...!

This story was initially reported in the U.K.'s Daily Mail, which is regarded as a tabloid. Here's how the Daily Mail is described in Wikipedia and many other sources. I'm taking this story with a lot of skepticism until I see it reported by more reliable sources (if there is such a thing in today's news services). If true, I stand to profit enormously with one of my investments, but for humanity's sake I hope this is tabloid fiction.

"The Daily Mail has been criticized for its unreliability, its printing of sensationalist and inaccurate scare stories about science and medical research, and for instances of plagiarism and copyright infringement."[/I] – Wikipedia

BUY! BUY! BUY! Right?

A long road to travel to recover one's 99% losses in prior IBIO investments, eh?

When is the next IBIO reverse split? How many have they done now? 3 or 4? I lost count. Will they also reduce the authorized shares this time along with outstanding shares, or leave it unchanged AGAIN so they can continue to dilute shareholders without limits?

I thought you were opposed to dilution. You've screamed about it on every other investment board, yet totally silent about it when it comes to IBIO. No concern at all in the previous RS where authorized share count was not impacted by the action. Puzzling.

....The new virus is even closer related to MERS, a deadlier type of coronavirus that kills up to a third of people it infects.Virologist Shi Zhengli, known as 'Batwoman' for her work on coronaviruses, led the discovery, published in a top scientific journal...

IBIO with news like this and being a vaccine player blue skies... In scenes eerily reminiscent of the beginnings of Covid, researchers at the infamous Wuhan Institute of Virology detected the new strain living within bats.

that’s a flexing of their muscles….

absolutely nothing wrong with that move, I’ll take it hands down all day long…!

IBio…!

IBIO approved to trade on the NASDAQ.  Moving from NYSE to Nasdaq

$3.92 + 6% Big news soon next major resistance at $5.60 

Feb 11th ..

IBIOOn watch for bird flu...Avian Influenza Stocks ListAvian Influenza ETFsRecent Avian Influenza NewsSymbolGrade  Our Relative Strength RatingName% ChangeIBIOBiBio, Inc.-8.06TRAWDTraws Pharma, Inc. -7.55INOFInovio Pharmaceuticals, Inc.-2.04MRNAFModerna, Inc.-2.24

IBIO...$3.72...🥳...Will watch for entry... Nice amount of Form4s...https://www.otcmarkets.com/stock/IBIO/disclosure

IBIO looking good 

Welcome. Yeah, the only thing going for it is the low float. If it happens, it will go up big, but then crash down quickly.

Thank you for your reply. I had actually bought some based on the recommendation but then did some DD and sold them. I didn’t see anything compelling. It’s one of those up in the air biotechs.
Once again thank you for your reply.

Best

I went through previous Con Artist CEO's like Tom Isett... Held since 2015 through 3 reverse splits.

My average is $1490.

I'm going to buy it down a little, but the Deputies of Tom Isett are running the place, so it could collapse and have another Reverse Split real easy.

My dad told me to buy IBIO, can anyone here point me to some useful info or knows what to expect if I invest here ?
Thank you in advance

Best

finally getting some lovin….

9-Mil shares - puny float - will rocket on ant new development

AJMHO

Your bs is done with IBIO Sir!!!

I want tons of $IBIO he he he!!!

Folks, the following song is definitely NOT the official 'Theme Song' for L.A. County, California, right now, Dudes!!!!

IBIO: Thanks for the heads-up, Commander Tw!!!

Insider buying $2.72 buy 5 insiders reported at 434pm low floater 

9,191A$ 2.7218,316

Otsuka

On February 25, 2024, the Company entered into the PD-1 Purchase Agreement with Otsuka pursuant to which the Company sold and assigned to Otsuka, and Otsuka purchased and assumed, all intellectual property rights directly related to the Company’s PD-1 Assets developed or held for development. The Company received an upfront payment of $1.0 million in cash at closing which is reported as a gain in the fiscal year ended June 30, 2024. The Company will also be eligible to receive additional contingent cash payments totaling up to $52.5 million upon the achievement of certain pre-specified clinical development and commercial milestones. The Company will recognize the potential milestone payments at the earlier of when the contingent consideration is realized or is realizable.

Affiliates of Eastern Capital Limited

On November 1, 2021, the Company and its subsidiary, iBio CDMO LLC (“iBio CDMO”, and collectively with the Company, the “Purchaser”) entered into a series of agreements (the “Transaction”) with College Station Investors LLC (“College Station”), and Bryan Capital Investors LLC (“Bryan Capital” and, collectively with College Station, “Seller”), each affiliates of Eastern Capital Limited (“Eastern,” a former significant stockholder of the Company) described in more detail below whereby in exchange for a certain cash payment and a warrant the Company:
(i) acquired both the Facility where iBio CDMO at that time and currently conducts business and also the rights as the tenant in the Facility’s ground lease;
(ii) acquired all of the equity owned by one of the affiliates of Eastern in the Company and iBio CDMO; and
(iii) otherwise terminated all agreements between the Company and the affiliates of Eastern.

The Facility is a life sciences building located on land owned by the Board of Regents of the Texas A&M University System (“Texas A&M”) and is designed and equipped for the manufacture of plant-made biopharmaceuticals. iBio CDMO had held a sublease for the Facility through 2050, subject to extension until 2060 (the “Sublease”) until the consummation of the sale of the Facility.